Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOD-5014 in healthy adult males
NCT02919800Phase 1Completed
- Sponsor
- OPKO Health
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in hemophilia A and hemophilia B (HB) comparing MOD-5014 with Placebo (2 arms). Primary endpoint: Composite safety and tolerability parameters at 30 days. Started Jan 2017; status: completed.
02
Drugs
LM007
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02919800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919800.